Researchers announced that pelacarsen, an experimental medication intended to reduce the risk of heart attacks and strokes, did not achieve its primary objectives in a large clinical study. The drug was tested on 8,350 adults who already had existing heart disease, with half receiving the medication and half receiving a placebo. While the drug successfully reduced Lp(a), a cholesterol-carrying protein associated with cardiovascular risk, by approximately 78%, this reduction failed to translate into protection against heart complications over the five-year study period.
The unexpected failure represents a significant setback for cardiovascular medicine. Elevated Lp(a) levels affect roughly 20% of the global population, or approximately one billion people, making it a widespread condition. Until recently, no medications were available to lower Lp(a) levels, but several pharmaceutical companies have developed new drugs capable of substantially reducing these levels in recent years. The high expectations surrounding such treatments reflected the substantial burden of cardiovascular disease, which remains the leading cause of death in developed countries and kills more than 900,000 Americans annually.
The study, led by cardiologist Steven Nissen at the Cleveland Clinic, targeted patients who appeared to manage their health responsibly through controlled cholesterol and blood pressure levels, proper nutrition, healthy weight maintenance, and regular exercise, yet still experienced heart attacks and strokes. Researchers had hoped to identify new therapeutic options for this population. Drug manufacturer Novartis, which sponsored the research, stated that the results provide meaningful insights into the relationship between Lp(a) and heart disease despite not achieving its stated goals.
Cardiovascular specialists have offered several potential explanations for the trial’s failure. The elevated Lp(a) may be a marker of cardiovascular risk rather than a direct cause of heart disease. Alternative theories include the possibility that longer treatment durations or earlier intervention before advanced arterial hardening develops might prove more effective. Some experts suggest the drug may only benefit patients with substantially higher Lp(a) levels or those with less controlled blood pressure and cholesterol. Additional trials testing competing Lp(a)-lowering drugs from manufacturers including Amgen and Eli Lilly are underway, with results expected within the coming years, suggesting the research field will continue pursuing this therapeutic approach.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI